Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cantargia AB ( (SE:CANTA) ) has shared an announcement.
Cantargia AB has appointed Dr. Hilde Steineger as its new CEO, effective September 1. Dr. Steineger, who brings extensive experience in biotechnology and business development, will lead the company at a critical stage, focusing on advancing its innovative antibody-based therapies and strategic partnerships. Her leadership is expected to enhance Cantargia’s growth and value creation, particularly following its recent agreement with Otsuka Pharmaceuticals. The appointment signifies a strategic move for Cantargia as it continues to mature and expand its clinical programs.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases. The company has established a platform based on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Cantargia’s oncology program includes the antibody nadunolimab (CAN04), which is being studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. The company also has a second development program, the antibody CAN10, targeting serious autoimmune and inflammatory diseases. Cantargia is listed on Nasdaq Stockholm.
YTD Price Performance: 72.19%
Average Trading Volume: 6,328,422
Technical Sentiment Signal: Hold
Current Market Cap: SEK723.5M
See more data about CANTA stock on TipRanks’ Stock Analysis page.